Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2.
Huang R, Warner Jenkins G, Kim Y, Stanfield RL, Singh A, Martinez-Yamout M, Kroon GJ, Torres JL, Jackson AM, Kelley A, Shaabani N, Zeng B, Bacica M, Chen W, Warner C, Radoicic J, Joh J, Dinali Perera K, Sang H, Kim T, Yao J, Zhao F, Sok D, Burton DR, Allen J, Harriman W, Mwangi W, Chung D, Teijaro JR, Ward AB, Dyson HJ, Wright PE, Wilson IA, Chang KO, McGregor D, Smider VV. Huang R, et al. Among authors: shaabani n. Proc Natl Acad Sci U S A. 2023 Sep 26;120(39):e2303455120. doi: 10.1073/pnas.2303455120. Epub 2023 Sep 18. Proc Natl Acad Sci U S A. 2023. PMID: 37722054 Free PMC article.
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
Geng ZZ, Atla S, Shaabani N, Vulupala V, Yang KS, Alugubelli YR, Khatua K, Chen PH, Xiao J, Blankenship LR, Ma XR, Vatansever EC, Cho CD, Ma Y, Allen R, Ji H, Xu S, Liu WR. Geng ZZ, et al. Among authors: shaabani n. J Med Chem. 2023 Aug 24;66(16):11040-11055. doi: 10.1021/acs.jmedchem.3c00221. Epub 2023 Aug 10. J Med Chem. 2023. PMID: 37561993 Free PMC article.
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants.
Hu Q, Zhao Y, Shaabani N, Lyu X, Powers C, Sun H, Cruz V, Stegman K, Xu J, Fossier A, Huang Y, Ho G, Kao Y, Wang Z, Wang Z, Hu Y, Zheng Y, Kyaw L, Zuluaga C, Wang H, Pei H, Allen R, Xie H, Ji H, Chen R. Hu Q, et al. Among authors: shaabani n. Mol Ther Nucleic Acids. 2022 Dec 13;30:465-476. doi: 10.1016/j.omtn.2022.10.021. Epub 2022 Nov 2. Mol Ther Nucleic Acids. 2022. PMID: 36345542 Free PMC article.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Among authors: shaabani n. Med. 2024 Feb 9;5(2):169-171. doi: 10.1016/j.medj.2024.01.013. Med. 2024. PMID: 38340710 Free article. No abstract available.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Among authors: shaabani n. Med. 2024 Jan 12;5(1):42-61.e23. doi: 10.1016/j.medj.2023.12.004. Epub 2024 Jan 4. Med. 2024. PMID: 38181791 Free article.
Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution.
Zhao F, Yuan M, Keating C, Shaabani N, Limbo O, Joyce C, Woehl J, Barman S, Burns A, Tran Q, Zhu X, Ricciardi M, Peng L, Smith J, Huang D, Briney B, Sok D, Nemazee D, Teijaro JR, Wilson IA, Burton DR, Jardine JG. Zhao F, et al. Among authors: shaabani n. Sci Signal. 2023 Aug 15;16(798):eabk3516. doi: 10.1126/scisignal.abk3516. Epub 2023 Aug 15. Sci Signal. 2023. PMID: 37582161
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
Geng ZZ, Atla S, Shaabani N, Vulupala VR, Yang KS, Alugubelli YR, Khatua K, Chen PC, Xiao J, Blankenship LR, Ma XR, Vatansever EC, Cho CC, Ma Y, Allen R, Ji H, Xu S, Liu WR. Geng ZZ, et al. Among authors: shaabani n. bioRxiv [Preprint]. 2023 Jan 18:2023.01.17.524469. doi: 10.1101/2023.01.17.524469. bioRxiv. 2023. PMID: 36711580 Free PMC article. Updated. Preprint.
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection.
Oh CK, Nakamura T, Beutler N, Zhang X, Piña-Crespo J, Talantova M, Ghatak S, Trudler D, Carnevale LN, McKercher SR, Bakowski MA, Diedrich JK, Roberts AJ, Woods AK, Chi V, Gupta AK, Rosenfeld MA, Kearns FL, Casalino L, Shaabani N, Liu H, Wilson IA, Amaro RE, Burton DR, Yates JR 3rd, Becker C, Rogers TF, Chatterjee AK, Lipton SA. Oh CK, et al. Among authors: shaabani n. Nat Chem Biol. 2023 Mar;19(3):275-283. doi: 10.1038/s41589-022-01149-6. Epub 2022 Sep 29. Nat Chem Biol. 2023. PMID: 36175661 Free PMC article.
57 results